Must psychologists change the way they analyze their data?

J Pers Soc Psychol

Department of Psychology, Cornell University, Ithaca, NY 14853, USA.

Published: October 2011

Wagenmakers, Wetzels, Borsboom, and van der Maas (2011) argued that psychologists should replace the familiar "frequentist" statistical analyses of their data with bayesian analyses. To illustrate their argument, they reanalyzed a set of psi experiments published recently in this journal by Bem (2011), maintaining that, contrary to his conclusion, his data do not yield evidence in favor of the psi hypothesis. We argue that they have incorrectly selected an unrealistic prior distribution for their analysis and that a bayesian analysis using a more reasonable distribution yields strong evidence in favor of the psi hypothesis. More generally, we argue that there are advantages to bayesian analyses that merit their increased use in the future. However, as Wagenmakers et al.'s analysis inadvertently revealed, they contain hidden traps that must be better understood before being more widely substituted for the familiar frequentist analyses currently employed by most research psychologists.

Download full-text PDF

Source
http://dx.doi.org/10.1037/a0024777DOI Listing

Publication Analysis

Top Keywords

bayesian analyses
8
evidence favor
8
favor psi
8
psi hypothesis
8
psychologists change
4
change analyze
4
analyze data?
4
data? wagenmakers
4
wagenmakers wetzels
4
wetzels borsboom
4

Similar Publications

Objective: This study aims to analyze the adverse drug events (ADEs) associated with tolvaptan in the Food and Drug Administration Adverse Event Reporting System database from the fourth quarter of 2009 to the second quarter of 2024.

Methods: After standardizing the data, various signal detection techniques, including Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network, and Multi-Item Gamma Poisson Shrinker, were employed for analysis.

Results: Among the 7,486 ADE reports where tolvaptan was the primary suspected drug, a total of 196 preferred terms were identified, spanning 24 different system organ classes.

View Article and Find Full Text PDF

Introduction: Eculizumab is a C5 complement inhibitor approved by the FDA for the targeted treatment of four rare diseases, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and aquaporin-4 immunoglobulin G-positive optic neuromyelitis optica spectrum disorders (AQP4-IgG+NMOSD). The current study was conducted to assess real-world adverse events (AEs) associated with eculizumab through data mining of the FDA Adverse Event Reporting System (FAERS).

Methods: Disproportionality analyses, including Reporting Ratio Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-Item Gamma Poisson Shrinker (MGPS) algorithms were used to quantify the signals of eculizumab-associated AEs.

View Article and Find Full Text PDF

Objective: Single inhaler triple therapy is widely used in Chronic Obstructive Pulmonary Disease (COPD) and asthma. This research aimed to analyze adverse events (AEs) associated with Budesonide/Glycopyrronium/Formoterol Fumarate (BUD/GLY/FOR) and Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI).

Methods: This is a cross-sectional study.

View Article and Find Full Text PDF

In this tutorial, we introduce the reader to analyzing ecological momentary assessment (EMA) data as applied in psychological sciences with the use of Bayesian (generalized) linear mixed-effects models. We discuss practical advantages of the Bayesian approach over frequentist methods and conceptual differences. We demonstrate how Bayesian statistics can help EMA researchers to (a) incorporate prior knowledge and beliefs in analyses, (b) fit models with a large variety of outcome distributions that reflect likely data-generating processes, (c) quantify the uncertainty of effect-size estimates, and (d) quantify the evidence for or against an informative hypothesis.

View Article and Find Full Text PDF

Background: Polyfluoroalkyl chemicals (PFCs) present potential health risks due to their persistence and bioaccumulation. However, there is currently insufficient evidence regarding their impact on cardiovascular disease (CVD). Consequently, it is imperative to investigate the correlation between PFCs and CVD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!